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Neisseria gonorrhoeae has developed antimicrobial resistance (AMR) to all drugs previously and currently
recommended for empirical monotherapy of gonorrhoea. In vitro resistance, including high-level, to the last option
ceftriaxone and sporadic failures to treat pharyngeal gonorrhoea with ceftriaxone have emerged. In response,
empirical dual antimicrobial therapy (ceftriaxone 250–1000 mg plus azithromycin 1–2 g) has been introduced in
several particularly high-income regions or countries. These treatment regimens appear currently effective and
should be considered in all settings where local quality assured AMR data do not support other therapeutic
options. However, the dual antimicrobial regimens, implemented in limited geographic regions, will not entirely
prevent resistance emergence and, unfortunately, most likely it is only a matter of when, and not if, treatment
failures with also these dual antimicrobial regimens will emerge. Accordingly, novel affordable antimicrobials for
monotherapy or at least inclusion in new dual treatment regimens, which might need to be considered for all
newly developed antimicrobials, are essential. Several of the recently developed antimicrobials deserve
increased attention for potential future treatment of gonorrhoea. In vitro activity studies examining collections
of geographically, temporally and genetically diverse gonococcal isolates, including multidrug-resistant strains
particularly with resistance to ceftriaxone and azithromycin, are important. Furthermore, understanding of
effects and biological fitness of current and emerging (in vitro induced/selected and in vivo emerged) genetic
resistance mechanisms for these antimicrobials, prediction of resistance emergence, time-kill curve analysis to
evaluate antibacterial activity, appropriate mice experiments, and correlates between genetic and phenotypic
laboratory parameters, and clinical treatment outcomes, would also be valuable. Subsequently, appropriately
designed, randomized controlled clinical trials evaluating efficacy, ideal dose, toxicity, adverse effects, cost, and
pharmacokinetic/pharmacodynamics data for anogenital and, importantly, also pharyngeal gonorrhoea, i.e.
because treatment failures initially emerge at this anatomical site. Finally, in the future treatment at first
health care visit will ideally be individually-tailored, i.e. by novel rapid phenotypic AMR tests and/or genetic
point of care AMR tests, including detection of gonococci, which will improve the management and public
health control of gonorrhoea and AMR. Nevertheless, now is certainly the right time to readdress the
challenges of developing a gonococcal vaccine.
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Introduction
The World Health Organization (WHO) estimated in 2008
that 106 million new gonorrhoea cases occur among adults
annually worldwide [1]. If the gonococcal infections are not
detected and/or appropriately treated, they can result in
severe complications and sequelae such as pelvic inflamma-
tory disease, infertility, ectopic pregnancy, first trimester
abortion, neonatal conjunctivitis leading to blindness and,
less frequently, male infertility and disseminated gonococcal
infections. Gonorrhoea also increases the transmission and
acquisition of HIV. Thus, gonorrhoea causes significant
morbidity and socioeconomic consequences globally [1, 2].
In the absence of a gonococcal vaccine, public health con-
trol of gonorrhoea is relying on effective, accessible and
affordable antimicrobial treatment, i.e., combined with ap-
propriate prevention, diagnostics (index cases and traced
sexual contacts), and epidemiological surveillance. The
antimicrobial treatment should cure individual gonorrhoea
cases, to reduce the risk of complications, and end further
transmission of the infection, which is a crucial to decrease
the gonorrhoea burden in a population.
Unfortunately, Neisseria gonorrhoeae has developed re-
sistance to all antimicrobials introduced for treatment of
gonorrhoea since the mid-1930s, when sulphonamides
were introduced. The resistance to many antimicrobials has
also rapidly, within only 1–2 decades, emerged and spread
internationally [3–6]. The bacterium has utilized mainly all
known mechanisms of antimicrobial resistance (AMR): in-
activation of the antimicrobial, alteration of antimicrobial
targets, increased export (e.g., through efflux pumps such
as MtrCDE) and decreased uptake (e.g. through porins
such as PorB). The mechanisms that change the permeabil-
ity of the gonococcal cell are particularly concerning be-
cause these decrease the susceptibility to a wide range of
antimicrobials with different modes of action, e.g., penicil-
lins, cephalosporins, tetracyclines and macrolides [3, 5–8].
At present, the prevalence of N. gonorrhoeae resistance to
most antimicrobials earlier recommended for treatment
worldwide, such as sulphonamides, penicillins, earlier gen-
eration cephalosporins, tetracyclines, macrolides and fluor-
oquinolones, is high internationally [2–15]. In most
countries, the only options for first-line empirical
antimicrobial monotherapy are currently the extended-
spectrum cephalosporins (ESCs) cefixime (oral) and par-
ticularly the more potent ceftriaxone (injectable) [2, 3, 5, 7,
8, 10–15].
Conventional antimicrobial treatment of gonorrhoea
Treatment of gonorrhoea is mainly administered directly
observed before any laboratory results are available, i.e., em-
pirical therapy using first-line recommendations according
to evidence-based management guidelines that are crucial
to regularly update based on high quality surveillancedata. Ideally, the recommended first-line therapy should be
highly effective, widely available and affordable in appropri-
ate quality and dose, lack toxicity, possible to administer as
single dose, and cure >95 % of infected patients [2, 16].
However, levels of >1 % and >3 % AMR in high-frequency
transmitting populations have also been suggested as
thresholds for altering recommended treatment [16, 17].
Additional criteria, e.g. prevalence, local epidemiology, diag-
nostic tests, transmission frequency, sexual contact tracing
strategies, and treatment strategies and cost, should ideally
also be considered in this decision and the identical AMR
threshold and recommended treatment regimen(s) may not
be the most cost-effective solution in all settings and popu-
lations [3, 18, 19].
Current antimicrobial treatment, ceftriaxone treatment
failures, ceftriaxone resistant strains, and dual therapy
During the latest decade, cefixime 400 mg × 1 orally or
ceftriaxone 125–1000 mg × 1 intramuscularly (IM) or
intravenously (IV) has been recommended first-line for
monotherapy of gonorrhoea in many countries globally
[3–5, 7–9, 18, 20, 21]. However, since the first treatment
failures with cefixime were verified in Japan in the early-
2000s [22], failures have been verified in many countries
worldwide, i.e. Norway, United Kingdom, Austria, France,
Canada, and South Africa [23–29]. Most worryingly, spor-
adic treatment failures with ceftriaxone (250–1000 mg × 1),
the last remaining option for empiric first-line monother-
apy in many countries, have been verified in Japan,
Australia, Sweden, and Slovenia [30–36]. The main charac-
teristics of the verified treatment failures with ceftriaxone
(n = 11) are described in Table 1.
Obviously, the number of verified treatment failures
with ceftriaxone is low internationally. However, most
likely these verified failures only represent the tip of the
iceberg, because very few countries have active and quality
assured surveillance and appropriately verify treatment
failures. It is essential to strengthen this surveillance and
follow-up of suspected and verified ceftriaxone treatment
failures. WHO publications [2, 9, 16] recommend labora-
tory parameters to verify treatment failures, which ideally
requires examining pre- and post-treatment isolates for
ESC MICs, molecular epidemiological genotype, and gen-
etic resistance determinants. Additionally, a detailed clin-
ical history that excludes reinfection and records the
treatment regimen(s) used is mandatory.
Briefly, the ceftriaxone MICs of the gonococcal isolates
causing the ceftriaxone treatment failures ranged from
0.016 to 4 mg/L. Seven (88 %) of the eight isolates geno-
typed with multilocus sequence typing (MLST) were
assigned to ST1901. Six (55 %) failures were caused by
gonococcal strains belonging to the N. gonorrhoeae mul-
tiantigen sequence typing (NG-MAST) ST1407 or genet-
ically closely related NG-MAST STs, such as ST2958,










Australia (n = 2),
2007 [31]
250 mg × 1 0.016-0.03
(Agar dilution)
41.4-50.3 ND/ST5, ST2740 Pharynx Ceftriaxone 500 mg × 1/ Ceftriaxone
1 g × 1
Japan (n = 1),
2009 [30]
1 g × 1 4.0b
(Etest, XDR)
0 ST7363/ST4220 Pharynx Nonec
Sweden (n = 1),
2010 [34]
250 mg × 1 and
500 mg × 1
0.125-0.25b
(Etest)
15.6-32.8 ST1901/ST2958 Pharynx Ceftriaxone 1 g × 1
Australia (n = 1),
2010 [32]




Pharynx Azithromycin 2 g × 1
Slovenia (n = 1),
2011 [36]




Pharynx Ceftriaxone 250 mg × 1 plus
azithromycin 1 g × 1
Australia (n = 2),
2011 [33]
500 mg × 1 0.03-0.06
(Agar dilution)
41.3-49.9 ST1901/ST225,
new variant of ST225
Pharynx Ceftriaxone 1 g × 1 plus azithromycin
2 g × 1 or Ceftriaxone 1 g × 1
Sweden (n = 3),
2013–2014 [35]




Pharynx Ceftriaxone 1 g × 1
aSimulation of time of free ceftriaxone above MIC (f T>MIC) based on mean pharmacokinetic parameter values. Data from Chisholm et al. [52]
bGenetic cephalosporin resistance determinants (penA, mtrR, penB) elucidated [3, 5–8]
cThe infection was considered to have resolved spontaneously within 3 months
MIC minimum inhibitory concentration, MLST multilocus sequence typing, NG-MAST Neisseria gonorrhoeae multi-antigen sequence typing, ND not determined,
ST sequence type, XDR extensively drug-resistant [9]
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long to NG-MAST genogroup 1407 [37]. However, the
failure to treat pharyngeal gonorrhoea in a female com-
mercial sex worker with ceftriaxone 1 g × 1 in Kyoto,
Japan, was caused by a strain assigned as MLST ST7363
and NG-MAST ST4220 (Table 1). This strain was the
first verified extensively drug-resistant (XDR [9]) N.
gonorrhoeae strain (‘H041’; the first gonococcal ‘super-
bug’), which displayed high-level resistance to ceftriax-
one (MIC = 2-4 mg/L) [30]. Only two years later (2011),
two additional superbugs were identified in men-who-
have-sex-with-men (MSM) in France [26] and Spain
[38], which are suspected to belong to the identical
strain (‘F89’) and may represent the first international
transmission of a high-level ceftriaxone resistant gonococ-
cal strain. In 2014, a ceftriaxone resistant strain with gen-
etic similarities to H041 was reported in Australia [39].
However, this strain had a lower ceftriaxone MIC com-
pared to H041 and F89 (MIC: 0.5 mg/L versus 2–4 mg/L
using Etest), and sporadic gonococcal strains with this
low-level ceftriaxone resistance have been previously de-
scribed internationally [25, 40, 41]. The main characteris-
tics of the verified superbugs and examples of sporadic
gonococcal strains with ceftriaxone MIC = 0.5 mg/L are
described in Table 2.
Briefly, the first verified gonococcal superbug H041
had a ceftriaxone MIC of 4 mg/L using Etest and was
assigned to NG-MAST ST4220 and MLST ST7363 [30],
an MLST clone that has been prevalent and caused
many of the early cefixime treatment failures in Japan.
The gonococcal strains causing these early cefixime
treatment failures had a mosaic penicillin-binding pro-
tein 2 (PBP2) X sequence variant [3, 8, 30, 42–44].However, H041 had developed also high-level ceftriaxone
resistance by 12 additional amino acid alterations in PBP2
X [30], of which the novel key resistance amino acid alter-
ations were A311V, T316P, T483S [45]. The A8806 strain
recently detected in Australia (ceftriaxone MIC = 0.5 mg/L)
showed some key genetic similarities to H041, including
the identical MLST ST7363, similar NG-MAST ST, and
shared two (A311V and T483S) of the three PBP2 alter-
ations pivotal to the high-level ceftriaxone resistance
[39, 45]. Noteworthy, three of the five additional isolates
with ceftriaxone MIC ≥ 0.5 mg/L were assigned as MLST
ST1901 and NG-MAST ST1407 (Table 2). This clone has
been traced back to 2003 in Japan, accounting for most of
the decreased susceptibility and resistance to ESCs in
Europe, and basically spread globally [3, 8, 23–27, 29, 32,
35–38, 43, 44, 46, 47]. Noteworthy, although ST1407 has
been the most prevalent NG-MAST ST of MLST ST1901
in Europe, many NG-MAST STs of this MLST clone have
been identified globally, particularly in Japan, where
ST1901 replaced ST7363 as the most prevalent MLST
clone already in the early 2000s [3, 8, 43, 44]. Most fre-
quently, this clone has had a mosaic PBP2 XXXIV [3, 8,
23, 27, 35, 36], however, in all these three isolates the
PBP2 had mutated and included one additional muta-
tion, i.e., A501P (French and Spanish strain) or T534A
(Swedish strain) [25, 26, 38]. Undoubtedly, the superbugs
and these additional sporadic strains illustrate that gono-
cocci have different ways to develop ceftriaxone, including
high-level, resistance and that only one or a few mutations
in PBP2 are required for ceftriaxone resistance in a large
proportion of strains circulating worldwide [3, 8, 14, 23–
27, 29, 30, 32, 35–40, 42–44, 46–49]. Several additional
ceftriaxone resistant strains may already be circulating but
Table 2 Main characteristics of the verified Neisseria gonorrhoeae superbugs and examples of sporadic gonococcal strains with
ceftriaxone MIC = 0.5 mg/L
Country, year Ceftriaxone MIC
(mg/L)
fT>MIC (hours) with ceftriaxone
250 mg × 1 (1 g × 1)a
MLST NG-MAST PBP2 sequence variant [30]
Japan, 2009
“H041” [30]
4 (Etest) 0-0 (0–5.6) ST7363 ST4220 C (X + 12 amino acid alterations; new key
resistance alterations: A311V, T316P, T483S [45]) b
France, 2011
“F89” [26]
2 (Etest) 0-0 (0–20.3) ST1901 ST1407 CI (XXXIV + A501P)b
Spain, 2011
“F89” [38]c
2 (Etest) 0-0 (0–20.3) ST1901 ST1407 CI (XXXIV + A501P)b
Japan, 2000–2001
[40]
0.5 (Agar dilution) 0-19.8 (11.1-49.8) ND ND X-variant (X + N575Δ + V576A)b
China, 2007
[41]
0.5 (Agar dilution) 0-19.8 (11.1-49.8) ND ST2288 XVII
Austria, 2011
[25]
0.5 (Etest) 0-19.8 (11.1-49.8) ST1901 ST1407 XXXIV + T534Ab
Australia, 2014
“A8806” [39]
0.5 (Agar dilution) 0-19.8 (11.1-49.8) ST7363 ST4015d C-variant (including two of the three key alterations
in H041: A311V and T483S)b
aMonte Carlo simulation, taking into account diversity inherent within patient populations, showing 95 % confidence intervals of time (h) of free ceftriaxone above
MIC (f T>MIC). Data from Chisholm et al. [52]
bMosaic PBP2 sequence variant [30]
cPossibly identical to the earlier identified French superbug [26] and represented the first international transmission of a high-level ceftriaxone resistant
gonococcal strain
dCompared to the superbug H041 [30], identical tbpB allele (10) and a porB allele (1059) that only differed by 6 %
MIC minimum inhibitory concentration, MLST multilocus sequence typing, NG-MAST Neisseria gonorrhoeae multi-antigen sequence typing, PBP2 penicillin-binding
protein 2, ND not determined, ST sequence type
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in many settings internationally. Most noteworthy, the
gonococcal strain detected in China in 2007 (ceftriaxone
MIC = 0.5 mg/L; non-mosaic PBP2 XVII) emphasizes that
gonococci can also develop ceftriaxone resistance without
a mosaic PBP2 [41]. In the non-mosaic PBP2 XVII, the
A501V and G542S mutations are suspected to be involved
in the ceftriaxone resistance, i.e. most likely together with
the resistance determinants mtrR and penB [3, 8, 41, 45,
50, 51]. Notably, particularly in Asia many strains with
a ceftriaxone MIC = 0.25 mg/L, i.e. ceftriaxone resistant
according to the European resistance breakpoints
(www.eucast.org), which lack a mosaic PBP2 are also
circulating. E.g., gonococcal strains with ceftriaxone
MIC = 0.25 mg/L and non-mosaic PBP2s have been de-
scribed in China (PBP2 XIII with A501TV and P551S
[41]), South Korea (PBP2 IV and V with G542S [48],
and XIII with A501TV and P551S [49]), and Vietnam
(PBP2 XVIII with A501T and G542S [51]).
Regarding pharmacodynamics, it has been suggested
that a time of free ESC above MIC (fT>MIC) of 20–24
hours is required for treatment with ESCs [52]. Applying
these figures on the gonococcal superbugs and other
sporadic strains with ceftriaxone MICs ≥ 0.5 mg/L, ac-
cording to Monte Carlo simulations sufficient fT>MIC is
not reached for any strain even at upper 95 % confi-
dence interval (CI) when using ceftriaxone 250 mg × 1.
Furthermore, even with ceftriaxone 1 g × 1, 20–24 hours
of fT>MIC will be reached in only very few, if any, pa-
tients infected with the superbugs and additionally it willnot be reached in many of the patients infected even
with the strains showing ceftriaxone MIC = 0.5 mg/L
(Table 2). However, several of the ceftriaxone treatment
failures have been caused by ceftriaxone susceptible gono-
coccal strains with a relatively low ceftriaxone MIC (0.016-
0.125 mg/L), and in many of these cases the fT>MIC should
have been substantially longer than 20–24 hours (Table 1).
These treatment failures were all for pharyngeal gonor-
rhoea and, most likely, reflect the difficulties in treating
pharyngeal gonorrhoea compared with urogenital gonor-
rhoea [3, 8, 9, 13, 30–36, 53–55]. Sufficient understanding
regarding the complex process when antimicrobials pene-
trate into the pharyngeal mucosa, where also the presence
of inflammation and pharmacokinetic properties of the
antimicrobial are important factors, is lacking. It is crucial
to elucidate why many antimicrobials, at least in some
patients, appear to achieve suboptimal concentrations in
tonsillar and other oropharyngeal tissues [55]. Appropri-
ate pharmacokinetic/pharmacodynamic studies and/or
optimized simulations with currently and futurely used
antimicrobials are essential for gonorrhoea, particularly
pharyngeal infection. It has also been suggested that
ESC resistance initially emerged in commensal Neisseria
spp., which act as a reservoir of AMR genes that are easily
transferred to gonococci through transformation, particu-
larly in pharyngeal gonorrhoea [3, 7–9, 42, 55–57].
Pharyngeal gonorrhoea is mostly asymptomatic, and
gonococci and commensal Neisseria spp. can coexist for
long time periods in the pharynx and share AMR genes
and other genetic material. Accordingly, an enhanced
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tions, such as MSM, with nucleic acid amplification tests
(NAATs) should be considered) and appropriate treatment
of pharyngeal gonorrhoea is imperative [2,3,8,13,56,].
The emergence of ceftriaxone treatment failures and par-
ticularly the superbugs with high-level ceftriaxone resist-
ance [26, 30, 38], combined with resistance to mainly all
other gonorrhoea antimicrobials, resulted in a fear that
gonorrhoea might become exceedingly-difficult-to-treat or
even untreatable. Consequently, the WHO published the
‘Global Action Plan to Control the Spread and Impact of
Antimicrobial Resistance in Neisseria gonorrhoeae’ [2, 58],
and the European Centre for Disease Prevention and Con-
trol (ECDC) [59] and the US Centers for Disease Control
and Prevention (CDC) published region-specific response
plans [60]. In general, all these plans request more holistic
actions, i.e., to improve early prevention, diagnosis, contact
tracing, treatment, including test-of-cure, and epidemio-
logical surveillance of gonorrhoea cases. It was also stated
essential to, nationally and internationally, significantly en-
hance the surveillance of AMR (maintaining culture is im-
perative), treatment failures and antimicrobial use/misuse
locally (strong antimicrobial stewardship crucial). Evidently,
gonococcal AMR data were lacking in many settings glo-
bally and, accordingly, the WHO Global Gonococcal Anti-
microbial Surveillance Programme (WHO Global GASP)
was reinitiated in 2009, in close liaison with other AMR
surveillance initiatives, to enable a coordinated global re-
sponse [58]. During recent years, dual antimicrobial
therapy (mainly ceftriaxone 250–500 mg × 1 and azithro-
mycin 1–2 g × 1) for empirical gonorrhoea treatment has
also been introduced in Europe, Australia, USA, Canada,
and some additional countries (Table 3).
Briefly, all regions or countries, with exception of Canada,
recommend only ceftriaxone plus azithromycin as first-line
[61–66]. However, the recommended doses of ceftriaxone
vary, i.e. range from 250 mg × 1 (USA and Canada) to
1 g × 1 (Germany), and the doses of azithromycin range
from 1 g × 1 (USA, Canada, UK and Australia) to 2 g × 1
(Europe) (Table 3). Appropriate clinical data to support the
different recommended doses of ceftriaxone and azithro-
mycin (in the combination therapy) for the currently cir-
culating gonococcal population are mainly lacking.
Instead, these treatment regimens were based on early
clinical efficacy trials [3, 7, 54, 67–72], pharmacokinetic/
pharmacodynamic simulations [52], in vitro AMR surveil-
lance data, anticipated trends in AMR, case reports of
treatment failures [22–26, 30, 31, 34, 36, 73], and expert
consultations. No other currently available and evaluated
injectable cephalosporin (e.g., ceftizoxime, cefoxitin with
probenecid, and cefotaxime) offers any advantages over cef-
triaxone in terms of efficacy and pharmokinetics/pharma-
codynamics, and efficacy for pharyngeal infection is less
certain [3, 8, 9, 21, 61, 65, 67–72, 74]. In Canada, also anoral first-line therapy is recommended, i.e. cefixime
800 mg × 1 plus azithromycin 1 g × 1. Mainly early evidence
indicated that cefixime 800 mg × 1 was safe and effective in
treating gonorrhoea [66, 69, 71, 72, 75, 76]. Pharmacody-
namic studies and/or simulations have also shown that,
compared to 400 mg × 1, 800 mg of cefixime (particularly
administered as 400 mg × 2, 6 hours apart) substantially in-
creases the fT>MIC of cefixime [22, 52]. However, in most
countries cefixime is only licensed for the currently or pre-
viously used 400 mg × 1, due to the more frequent gastro-
intestinal adverse effects observed with 800 mg × 1 [70],
and treatment failures with also cefixime 800 mg × 1 have
been verified [28].
Two different novel dual antimicrobial regimens have
also been evaluated for treatment of uncomplicated uro-
genital gonorrhoea, i.e., gentamicin (240 mg × 1 IM) plus
azithromycin (2 g × 1 orally), and gemifloxacin (320 mg × 1
orally) plus azithromycin (2 g × 1 orally) [77]. The cure rate
was 100 % with gentamicin + azithromycin and 99.5 % with
gemifloxacin + azithromycin, but gastrointestinal adverse
effects were frequent. E.g., 3.3 % and 7.7 % of patients, re-
spectively, vomited within one hour of treatment, which
necessitated retreatment with ceftriaxone and azithromycin
[77]. Nevertheless, these two therapeutic regimens can be
considered in the presence of ceftriaxone resistance, treat-
ment failure with recommended regimen, or ESC allergy.
Future treatment of gonorrhoea
Future treatment should be in strict concordance with
continuously updated evidence-based management guide-
lines, informed by quality assured surveillance of local
AMR and also treatment failures. Dual antimicrobial ther-
apy (ceftriaxone and azithromycin [61–66]), which also
eradicates concurrent chlamydial infections and many
concurrent Mycoplasma genitalium infections, should be
considered in all settings where local quality assured AMR
data do not support other therapeutic options. Despite
that the dual antimicrobial regimens with ceftriaxone and
azithromycin may not entirely prevent resistance emer-
gence [3, 8, 78], they will mitigate the spread of resistant
strains. Nevertheless, after strict evaluation (effectiveness
and compliance) multiple doses of single antimicrobials
should also be considered. An oral treatment regimen
(single or dual antimicrobials) would be exceedingly valu-
able and also allow patient-delivered partner therapy that
at least in some settings may decrease the gonorrhoea
prevalence at population level [79, 80].
Ideally, treatment at first health care visit will also be
individually-tailored, i.e. by novel rapid phenotypic AMR
tests, e.g. broth microdilution MIC assays, or genetic
point of care (POC) AMR tests, including detection of
gonococci. This will ensure a rational antimicrobial use
(including sparing last-line antimicrobials), timely notifi-
cation of sexual contacts, slow the AMR development,
Table 3 Recommended and alternative treatments for uncomplicated Neisseria gonorrhoeae infections of the urethra, cervix, rectum and pharynx in adults and youth in Europe,
United Kingdom, Germany, Australia, USA, and Canada





500 mg × 1 IM
Ceftriaxone 500 mg × 1 IM Ceftriaxone
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Ceftriaxone 500 mg × 1 IM Ceftriaxone
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1 g × 1 orally
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If IM/IV injection
is not possible:
Alternative treatments are not
recommended because of high
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It is strongly recommended that
treatment be guided by antimicrobial
susceptibility test results to determine
the appropriate antimicrobial agent in
consultation with an expert in infectious
diseases and local public health
authorities.
PLUS → Gemifloxacin
320 mg× 1 orally
PLUS
Azithromycin
2 g × 1




240 mg× 1 IM
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cCo-infection with Chlamydia trachomatis is common in young (<30 years) heterosexual individuals and men who have sex with men (MSM) with gonorrhoea. If treatment for gonorrhoea does not include azithromycin,















Unemo BMC Infectious Diseases  (2015) 15:364 Page 9 of 15and improve the public health control of both gonor-
rhoea and AMR [3, 4, 6, 81, 82]. No commercially avail-
able gonococcal NAAT detects any AMR determinants.
However, laboratory-developed NAATs have been designed
and used for identification of genetic AMR determinants
involved in resistance to penicillins, tetracyclines, macro-
lides, fluoroquinolones, cephalosporins, and multidrug-
resistance [3–7, 83–87]. Some “strain-specific” NAATs
detecting the key ESC resistance mutations in the superb-
ugs H041 [30] and F89 [26, 38] have also been developed
[88, 89]. However, genetic AMR testing will not entirely
replace phenotypic AMR testing because the relationships
between phenotypes and genotypes are not ideal, genetic
methods can only identify known AMR determinants, the
sensitivity and/or specificity in the prediction of AMR or
antimicrobial susceptibility is suboptimal (particularly for
ESCs with their ongoing resistance evolution involving
many different genes, mutations, and their epistasis), and
new AMR determinants continuously evolve [3–5, 8, 14].
Tests requiring continual updating with new targets will
not be profitable for commercial companies manufacturing
NAATs. In addition, several of the gonococcal AMR deter-
minants, e.g. mosaic penA alleles, originate in commensal
Neisseria species, which makes it difficult to predict gono-
coccal AMR in pharyngeal samples [3, 8, 9]. Further
research is crucial to continuously identify new AMR deter-
minants and appropriately evaluate how current and future
molecular AMR assays can supplement phenotypic AMR
surveillance and ultimately guide individually-tailored treat-
ment [3, 4, 6, 8, 14]. At present, at least for AMR surveil-
lance ciprofloxacin susceptibility is relatively easy to
predict, azithromycin susceptibility or resistance can be in-
dicated, and decreased susceptibility or resistance to ESCs
can be predicted, although with a low specificity, by detect-
ing mosaic penA alleles. Nevertheless, also non-mosaic
PBP2 sequences can cause ceftriaxone resistance [41, 48,
49, 51]. High-throughput genome sequencing [46, 47, 90–
92], transcriptomics and other novel technologies will likely
revolutionize the genetic AMR prediction and molecular
epidemiological investigations of both gonococcal isolates
and gonococcal NAAT positive samples.
Future treatment options for gonorrhoea
The current dual antimicrobial treatment regimens (ceftri-
axone plus azithromycin [61–66]) appear to be effective.
However, the susceptibility to ceftriaxone in gonococci
has decreased globally, azithromycin resistance is rela-
tively prevalent in many countries, concomitant resistance
to ceftriaxone and azithromycin has been identified in sev-
eral countries, and the dual antimicrobial regimens are
not affordable in many less-resourced settings [3, 8, 14,
15, 18, 78]. Furthermore, treatment failures with even azi-
thromycin 2 g × 1 have been verified [93–95] and gono-
coccal strains with high-level resistance to azithromycin(MIC ≥ 256 mg/L) have been described in Scotland [96],
United Kingdom [97], Ireland [98], Italy [99], Sweden
[100], USA [101], Argentina [102], and Australia [103].
Accordingly, no treatment failure with dual antimicrobial
therapy (ceftriaxone 250–500 mg × 1 plus azithromycin
1–2 g × 1) has been verified yet, nevertheless, most likely
it is only a matter of when, and not if, treatment failures
with these dual antimicrobial regimens will emerge. Con-
sequently, novel affordable antimicrobials for monother-
apy or at least inclusion in new dual treatment regimens
for gonorrhoea, which might need to be considered for all
newly designed antimicrobials, are essential.
The earlier frequently used aminocyclitol spectinomycin
(2 g × 1 IM) is effective for treatment of anogenital gonor-
rhoea, however, the efficacy against pharyngeal infection is
low (51.8 %; 95 %CI: 38.7 %-64.9 %) [53] and it is currently
not available in many countries [3, 61, 62, 65]. However,
the in vitro susceptibility to spectinomycin is exceedingly
high worldwide, including in South Korea where it has
been very frequently used for treatment [3, 5, 7, 8, 18, 49,
51, 61, 104–109]. Accordingly, in South Korea 53-58 % of
gonorrhoea patients in 2002–2006 [109] and 52-73 % in
2009–2012 were treated with spectinomycin [49]. Despite
this exceedingly high spectinomycin usage, spectinomycin
resistance has not been reported since 1993 in South
Korea [49]. Thus, the spread of spectinomycin resistance
in the 1980s [110–112] may reflect more uncontrolled
usage of spectinomycin and the transmission of some few
successful spectinomycin resistant gonococcal strains. Re-
search regarding biological fitness cost of spectino-
mycin resistance would be valuable, and in fact
spectinomycin might be underestimated for treatment
of gonorrhoea. This is particularly in dual antimicrobial
therapy together with azithromycin 1–2 g × 1, which
are alternative therapeutic regimens recommended in
the European [61] and Canadian [66] gonorrhoea man-
agement guidelines, that will also cover pharyngeal
gonorrhoea and potentially mitigate emergence of re-
sistance to both spectinmycin and azithromycin.
Other “old” antimicrobials that have been suggested for
future empirical monotherapy of gonorrhoea include the
injectable carbapenem ertapenem [113, 114], oral fosfo-
mycin [115], and injectable aminoglycoside gentamicin,
which has been used as first-line treatment, 240 mg × 1
IM together with doxycycline in syndromic management,
in Malawi since 1993 without any reported emergence of
in vitro resistance [3, 7, 61, 65, 67, 77, 116–119]. However,
disadvantages with these antimicrobials include that
in vitro resistance is rapidly selected (fosfomycin) or de-
creased susceptibility already exist (ertapenem [113, 114]),
evidence-based correlates between MICs, pharmacoki-
netic/pharmacodynamic parameters and gonorrhoea
treatment outcome are lacking (gentamicin, fosfomycin
and ertapenem), and mainly no recent clinical data exist
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extragenital gonorrhoea (gentamicin, fosfomycin and erta-
penem). Consequently, these antimicrobials are most
likely mainly options for ceftriaxone-resistant gonorrhoea,
ESC allergy and/or in noval dual antimicrobial treatment
regimens. Nevertheless, some small observational or con-
trolled studies mainly from the 1970s and 1980s evaluated
gentamicin for monotherapy of gonorrhoea. Two recent
meta-analyses of several of these studies reported that a
single dose of gentamicin resulted in cure rates of
only 62-98 % [119] and a pooled cure rate of 91.5 %
(95 %CI: 88-94 %) [118]. However, these early gentami-
cin studies were mainly small, of low quality and in general
provided insufficient data. Consequently, a multi-centre
(n = 8), parallel group, investigator-blinded, non-inferiority,
randomized, controlled Phase 3 clinical trial has been re-
cently initiated. This study aims to recruit 720 patients with
uncomplicated urogenital, pharyngeal and rectal gonor-
rhoea. Treatment with gentamicin 240 mg × 1 IM (n = 360)
compared to ceftriaxone 500 mg × 1 IM (n = 360), plus azi-
thromycin 1 g × 1 orally to each arm, will be evaluated, in
regard to clinical effectiveness, cost-effectiveness and safety
(www.research.uhb.nhs.uk/gtog).
Many derivates of earlier used antimicrobials have also
been evaluated in vitro against gonococcal strains recent
years. For example, several new fluoroquinolones, e.g.
avarofloxacin (JNJ-Q2), sitafloxacin, WQ-3810, and dela-
floxacin, have shown relatively high potency against gono-
cocci, including ciprofloxacin-resistant isolates [120–123].
The fluorocycline eravacycline (TP-434) and glycylcycline
tigecycline (family: tetracyclines) also appear to be effect-
ive against gonococci [124, 125]. Nevertheless, a small
fraction of administered tigecycline is excreted unchanged
in urine, which might question the use in gonorrhoea
treatment [126–128]. The lipoglycopeptide dalbavancin
and two new 2-acyl carbapenems (SM-295291 and
SM-369926) have shown a high activity against a lim-
ited number of gonococcal isolates [129, 130]. Finally,
the two “bicyclic macrolides” modithromycin (EDP-420)
and EDP-322 displayed relatively high activity against
azithromycin-resistant, ESC-resistant and multidrug-
resistant (MDR) gonococci, but high-level azithromycin re-
sistant gonococcal isolates (MIC ≥ 256 mg/L) were resistant
also to modithromycin and EDP-322 [131]. Unfortunately,
no clinical efficacy data for treatment of gonorrhoea exist
for any of these antimicrobials. More advanced in the de-
velopment is the novel oral fluoroketolide solithromycin
(family: macrolides) that has proved to have a high activity
against gonococci, including azithromycin-resistant, ESC-
resistant and MDR isolates [132]. Solithromycin has three
binding sites on the bacterial ribosome (compared with two
for other macrolides), which likely result in a higher anti-
bacterial activity and delay resistance emergence [133].
However, gonococcal strains with high-level azithromycinresistance (MIC ≥ 256 mg/L) appear to be resistant also to
solithromycin (MICs = 4-32 mg/L) [132]. Solithromycin is
well absorbed orally, with high plasma levels, intracellular
concentrations and tissue distribution, has a long post-
antimicrobial effect, and a 1.6 g × 1 oral dose is well-
tolerated [134]. A minor Phase 2 single-center, open-label
study showed that solithromycin (1.2 g × 1) treated all 22
evaluable patients with uncomplicated urogenital gonor-
rhoea [135]. An open-label, randomized, multi-centre
Phase 3 clinical trial is currently recruiting participants
with uncomplicated urogenital gonorrhoea. The study
aims to include 300 participants and solithromycin 1 g × 1
orally will be compared to a dual antimicrobial regimen,
i.e. ceftriaxone 500 mg × 1 plus azithromycin 1 g × 1
(www.clinicaltrials.gov).
Despite that derivates of “old” antimicrobials are devel-
oped, it is essential to develop novel antimicrobial targets,
compounds and treatment strategies. Drugs with multiple
targets might be crucial to mitigate resistance emergence.
Recent years, several antimicrobials or other compounds,
using new targets or antibacterial strategies, have been de-
veloped and shown a potent in vitro activity against gono-
coccal isolates. E.g., new protein synthesis inhibitors such
as pleuromutilin BC-3781 and the boron-containing in-
hibitor AN3365; LpxC inhibitors; species-specific FabI
inhibitors such as MUT056399; and novel bacterial topo-
isomerase inhibitors with target(s) different from the
fluoroquinolones such as VXc-486 (also known as
VT12-008911) and ETX0914 (also known as AZD0914)
[136–143]. The novel oral spiropyrimidinetrione ETX0914,
which additionally has a new mode-of-action [144, 145], is
most advanced in the development. No resistance was ini-
tially observed examining 250 temporally, geographically
and genetically diverse isolates including many fluoroquino-
lone-, ESC- and multidrug-resistant isolates [141]. Recently,
it was shown that the susceptibility to ETX0914 among
873 contemporary clinical isolates from 21 European
countries was high and no resistance was indicated
[143]. ETX0914 administered orally has good target tissue
penetrance, good bioavailability, high safety and tolerability
(200–4000 mg × 1 orally well tolerated in healthy adult sub-
jects in both fed and fasted state) as indicated from initial
animal toxicology study and Phase 1, randomized, placebo-
controlled trial conducted in 48 healthy subjects [146, 147].
An open-label, randomized, multi-centre Phase 2 clinical
trial is currently recruiting patients with uncomplicated
urogenital gonorrhoea. The study aims to include 180 par-
ticipants and treatment with ETX0914 2 g orally (n = 70)
and ETX0914 3 g orally (n = 70) will be evaluated against
ceftriaxone 500 mg (n = 40) (www.clinicaltrials.gov).
Conclusions
Dual antimicrobial therapy of gonorrhoea (ceftriaxone
250 mg-1 g plus azithromycin 1–2 g [61–66]) appears
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tings where local quality assured AMR data do not support
other therapeutic options. These dual antimicrobial regi-
mens may not entirely prevent resistance emergence
in gonococci [3, 8, 78], but they will mitigate the
spread of resistant strains. Unfortunately, the first fail-
ure with dual antimicrobial therapy will most likely
soon be verified. Novel affordable antimicrobials for
monotherapy or at least inclusion in new dual treat-
ment regimens for gonorrhoea are essential and sev-
eral of the recently developed antimicrobials deserve
increased attention. In vitro activity studies examining
collections of geographically, temporally and genetic-
ally diverse gonococcal isolates, including MDR
strains, particularly with ESC resistance and azithro-
mycin resistance are important. Furthermore, know-
ledge regarding effects and biological fitness of
current and emerging (in vitro selected and in vivo
emerged) genetic resistance mechanisms for these an-
timicrobials, prediction of resistance emergence, time-
kill curve analysis to evaluate antibacterial activity,
and correlates between genetic and phenotypic labora-
tory parameters, and clinical treatment outcomes,
would also be valuable. Subsequently, appropriately
designed, randomized and controlled clinical trials
evaluating efficacy, ideal dose, adverse effects, cost,
and pharmacokinetic/pharmacodynamics data for ano-
genital and, importantly, also pharyngeal gonorrhoea,
i.e. because treatment failures initially emerge at this
anatomical site, are crucial. Finally, several examples
of “thinking out of the box” for future management
of gonorrhoea have also been developed recently [3]
and now is certainly the right time to readdress the
challenges of developing a gonococcal vaccine [148].Abbreviations
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